Citadel Advisors
COEPW

Citadel Advisors’s Coeptis Therapeutics Warrants COEPW Stock Holding History

Citadel Advisors’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,023
Closed -$107 – 13135
2025
Q4 		$107 Sell
10,023
-36
-0.4% -$1 ﹤0.01% 12507
2025
Q3 		$300 Buy
+10,059
New +$266 ﹤0.01% 12617
2025
Q2 		– Sell
-11,834
Closed -$130 – 12847
2025
Q1 		$130 Buy
11,834
+689
+6% +$18 ﹤0.01% 14325
2024
Q4 		$245 Sell
11,145
-638
-5% -$15 ﹤0.01% 14360
2024
Q3 		$177 Buy
11,783
+253
+2% +$5 ﹤0.01% 14079
2024
Q2 		$346 Buy
11,530
+100
+0.9% +$3 ﹤0.01% 14017
2024
Q1 		$291 Buy
+11,430
New +$469 ﹤0.01% 14370
2022
Q2 		– Sell
-602,734
Closed -$49K – 13001
2022
Q1 		$49K Sell
602,734
-122
-0% -$20 ﹤0.01% 12795
2021
Q4 		$195K Buy
602,856
+2,764
+0.5% +$920 ﹤0.01% 11884
2021
Q3 		$155K Hold
600,092
– – ﹤0.01% 12340
2021
Q2 		$324K Sell
600,092
-200
-0% -$102 ﹤0.01% 11080
2021
Q1 		$261K Buy
+600,292
New +$563K ﹤0.01% 11147

Other funds holding COEPW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's COEPW Position: Q1 2026 in Review

Citadel Advisors sold out of Coeptis Therapeutics Warrants (COEPW) in Q1 2026, closing a stake of 10,023 shares — an estimated $107 sold.

Citadel Advisors first reported a position in COEPW in Q1 2021 and held it in 12 quarters. The position peaked at $324K in Q2 2021. 10 funds tracked by Wall St. Rank hold COEPW as of Q1 2026.

  • Citadel Advisors reported no remaining Coeptis Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,023 Coeptis Therapeutics Warrants shares in Q1 2026, an estimated $107.
  • Citadel Advisors first reported a position in Coeptis Therapeutics Warrants in Q1 2021 and held it in 12 quarters.
  • Citadel Advisors's Coeptis Therapeutics Warrants position peaked at $324K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.